

KAKKIS EMIL D  
Form 4  
May 05, 2008

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
KAKKIS EMIL D

2. Issuer Name and Ticker or Trading Symbol  
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)  
  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
Chief Medical Officer

(Last) (First) (Middle)  
  
C/O BIOMARIN  
PHARMACEUTICAL INC., 105  
DIGITAL DRIVE  
  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
04/30/2008

NOVATO, CA 94949  
  
(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or Disposed of (A) or (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	04/30/2008 <sup>(1)</sup>		P	V 1,640 A \$ 10.37	162,804	D	
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	M	18,000 A \$ 4	180,804	D	
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	1,501 D \$ 37.31	179,303	D	
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	100 D \$ 37.33	179,203	D	
	05/01/2008 <sup>(2)</sup>	05/01/2008	S	300 D	178,903	D	

Edgar Filing: KAKKIS EMIL D - Form 4

Common Stock						\$ 37.34		
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	500	D	\$ 37.35	178,403	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	300	D	\$ 37.36	178,103	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	500	D	\$ 37.39	177,603	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	400	D	\$ 37.4	177,203	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	200	D	\$ 37.41	177,003	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	100	D	\$ 37.42	176,903	D
Common Stock	05/01/2008	05/01/2008	S	200	D	\$ 37.43	176,703	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	900	D	\$ 37.46	175,803	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	1,200	D	\$ 37.47	174,603	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	599	D	\$ 37.48	174,004	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	1,095	D	\$ 37.49	172,909	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	800	D	\$ 37.5	172,109	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	900	D	\$ 37.51	171,209	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	2,900	D	\$ 37.54	168,309	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	2,000	D	\$ 37.55	166,309	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	406	D	\$ 37.56	165,903	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	1,399	D	\$ 37.57	164,504	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	800	D	\$ 37.59	163,704	D
Common Stock	05/01/2008 <sup>(2)</sup>	05/01/2008	S	900	D	\$ 37.65	162,804	D
							4,654	I

Common  
Stock

Shares  
held by  
spouse

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
Stock Option (right to buy)	\$ 4	05/01/2008 <sup>(2)</sup>	05/01/2008	M	18,000	12/24/1998 <sup>(3)</sup> 06/21/2008	Common Stock 18,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KAKKIS EMIL D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			Chief Medical Officer	

## Signatures

G. Eric Davis,  
Attorney-in-Fact  
Date: 05/05/2008

\*\*Signature of Reporting Person

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to the Employee Stock Purchase Plan.

Edgar Filing: KAKKIS EMIL D - Form 4

- (2) Transaction made pursuant to a Rule10b5-1 Trading Plan executed March 5, 2008.
- (3) Original option grant vested 6/48ths on 12/24/1998 and 1/48th on the 24th of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.